AKT1 and prostate carcinoma: Akt, well known as a key survival factor involved in the control of cell proliferation and apoptosis, and described as a therapeutic target used in oncology, shows a reduced activation, supporting CU and LF’s roles as inhibitors of the growth, proliferation, adhesion, and invasion of prostate cancer cells [37].